InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (2 ops.)
Discover the complete record of transactions filed by Johnson David Michael, Director. Officer active across 2 companies, notably Zentalis Pharmaceuticals, Inc.. Cumulatively, 10 disclosures have been logged. Total volume traded: €598k. The latest transaction was filed on 10 June 2022 — Acquisition. Regulator: SEC (Form 4). The full history is free.
Declarations10 total
€42,4893,000 shares@ €14.1630.0050% mcap100.0% of flow
Common Stock
SEC:0000899243-22-022456:0·
Ideal exit: 7 Mar 2023 (T+270)
024,871 shares0
Common Stock
SEC:0001725160-22-000121:0·
07,500 shares0
Common Stock
SEC:0001725160-21-000242·
07,500 shares0
Common Stock
SEC:0001725160-21-000242:0·
0139,672 shares0
Common Stock
SEC:0000899243-21-042361·
0139,672 shares0
Common Stock
SEC:0000899243-21-042361:0·
€277,6864,892 shares@ €56.76330.096% mcap100.0% of flow
Common Stock
SEC:0001725160-21-000197·
€277,6864,892 shares@ €56.76330.096% mcap50.0% of flow
Common Stock
SEC:0001725160-21-000197:0·
05,000 shares0
Common Stock
SEC:0001725160-21-000142·
05,000 shares0
Common Stock
SEC:0001725160-21-000142:0·
10 of 10 declarations
About Johnson David Michael
David Michael Johnson serves as a Director at Zentalis Pharmaceuticals, Inc. and Aura Biosciences, Inc. In these roles, he participates in corporate governance and strategic decision-making. Johnson leverages his expertise to help define the strategic directions of the companies, ensuring they comply with regulatory requirements and achieve their objectives.
